Related Experiment Video
Updated: Apr 3, 2026
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
Nivolumab in combination with ipilimumab for the treatment of melanoma
Rajasekharan Somasundaram, Meenhard Herlyn1
1a The Wistar Institute, 3601 Spruce St, Philadelphia, PA19104, USA.
Abstract:
Melanoma patients develop resistance to most therapies, including chemo- and targeted-therapy drugs. Single-agent therapies are ineffective due to the heterogeneous nature of tumors comprising several subpopulations. Treatment of melanoma with immune-based therapies such as anti-cytotoxic T-lymphocyte activation-4 and anti-programmed death-1 antibodies has shown modest but long-lasting responses. Unfortunately, only subsets of melanoma patients respond to antibody-based therapies. Heterogeneity in lymphocyte infiltration and low frequency of anti-melanoma-reactive T-cells in tumor lesions are partly responsible for a lack of response to antibody-based therapies. Both antibodies have same biological function but they bind to different ligands at various phases of T-cell activity. Thus, combination therapy of antibodies has shown superior response rates than single-agent therapy. However, toxicity is a cause of concern in these therapies. Future identification of therapy-response biomarkers, mobilization of tumor-reactive T-cell infiltration using cancer vaccines, or non-specific targeted-therapy drugs will minimize toxicity levels and provide long-term remissions in melanoma patients.
Insights
Melanoma patients often resist therapies. Combining immune checkpoint inhibitors, like anti-cytotoxic T-lymphocyte activation-4 and anti-programmed death-1 antibodies, improves responses but raises toxicity concerns, necessitating biomarker research for better melanoma treatment.
Area of Science:
- Oncology
- Immunology
- Dermatology
Background:
- Melanoma exhibits significant heterogeneity, leading to resistance against conventional chemotherapy and targeted therapies.
- Current immune-based therapies, including anti-cytotoxic T-lymphocyte activation-4 (CTLA-4) and anti-programmed death-1 (PD-1) antibodies, offer durable responses in a subset of melanoma patients.
- Limited T-cell infiltration and low frequency of anti-melanoma reactive T-cells contribute to non-response in some patients.
Purpose of the Study:
- To review the efficacy and challenges of current melanoma therapies.
- To explore the potential of combination immunotherapy for melanoma treatment.
- To identify future strategies for improving melanoma patient outcomes and reducing treatment toxicity.
Main Methods:
- Literature review of melanoma treatment strategies.
- Analysis of immune checkpoint inhibitor mechanisms and clinical outcomes.
- Discussion of therapeutic resistance and response heterogeneity in melanoma.
Main Results:
- Single-agent therapies are often ineffective due to tumor heterogeneity.
- Combination therapy with anti-CTLA-4 and anti-PD-1 antibodies demonstrates superior response rates compared to single-agent approaches.
- Despite improved efficacy, combination therapies present significant toxicity concerns.
Conclusions:
- Combination immunotherapy holds promise for enhancing melanoma treatment responses.
- Further research into therapy-response biomarkers and novel strategies like cancer vaccines is crucial.
- Future directions aim to minimize toxicity and achieve long-term remission in melanoma patients.
Related Concept Videos
01:27Tumor Immunotherapy
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:50Combination Therapies and Personalized Medicine
02:56Treatment Resistent Cancers
02:56Treatment Resistant Cancers
01:30Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...